Hurley Capital’s Pasithea Therapeutics KTTA Stock Holding History

Hurley Capital’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.61K	Buy	7,000 +3,311	+90%	+$2.28K	﹤0.01%	494
2026 Q1	$2.74K	Hold	3,689	–	–	﹤0.01%	543
2025 Q4	$4.76K	Hold	3,689	–	–	﹤0.01%	425
2025 Q3	$2.7K	Hold	3,689	–	–	﹤0.01%	495
2025 Q2	$2.66K	Hold	3,689	–	–	﹤0.01%	391
2025 Q1	$4.8K	Buy	+3,689	New	+$6.55K	﹤0.01%	378

Other funds holding KTTA

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Hurley Capital's KTTA Position: Q2 2026 in Review

Hurley Capital increased its Pasithea Therapeutics (KTTA) stake by 90% in Q2 2026, buying an estimated $2.28K and bringing the position to 7,000 shares worth $3.61K. The position accounts for ﹤0.01% of the portfolio, ranked #494.

Hurley Capital first reported a position in KTTA in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.8K in Q1 2025. 6 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

Hurley Capital held 7,000 shares of Pasithea Therapeutics worth $3.61K as of Q2 2026.
Hurley Capital bought 3,311 Pasithea Therapeutics shares in Q2 2026, an estimated $2.28K.
Pasithea Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #494 holding.
Hurley Capital first reported a position in Pasithea Therapeutics in Q1 2025 and has held it in 6 quarters since.
Hurley Capital's Pasithea Therapeutics position peaked at $4.8K in Q1 2025.
6 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.